AR036833A1 - Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular. - Google Patents
Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular.Info
- Publication number
- AR036833A1 AR036833A1 ARP020103877A ARP020103877A AR036833A1 AR 036833 A1 AR036833 A1 AR 036833A1 AR P020103877 A ARP020103877 A AR P020103877A AR P020103877 A ARP020103877 A AR P020103877A AR 036833 A1 AR036833 A1 AR 036833A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibodies
- human
- polynucleotides
- preparation
- join
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34365701P | 2001-10-18 | 2001-10-18 | |
| US37771602P | 2002-05-02 | 2002-05-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036833A1 true AR036833A1 (es) | 2004-10-06 |
Family
ID=26993561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020103877A AR036833A1 (es) | 2001-10-18 | 2002-10-16 | Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7462696B2 (enExample) |
| EP (1) | EP1438339A4 (enExample) |
| JP (2) | JP2005528884A (enExample) |
| KR (1) | KR20050037478A (enExample) |
| CN (1) | CN1606569A (enExample) |
| AR (1) | AR036833A1 (enExample) |
| BR (1) | BR0213968A (enExample) |
| CA (1) | CA2463943A1 (enExample) |
| CO (1) | CO5370684A1 (enExample) |
| DO (1) | DOP2002000494A (enExample) |
| HU (1) | HUP0600335A2 (enExample) |
| IL (1) | IL161411A0 (enExample) |
| MX (1) | MXPA04003508A (enExample) |
| PE (1) | PE20030473A1 (enExample) |
| PL (1) | PL374304A1 (enExample) |
| RU (1) | RU2317998C2 (enExample) |
| UY (1) | UY27499A1 (enExample) |
| WO (1) | WO2003033674A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040191246A1 (en) * | 2003-02-26 | 2004-09-30 | Connelly Patrick R. | Process for in vivo treatment of specific biological targets in bodily fluid |
| US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US20090162382A1 (en) * | 2002-03-01 | 2009-06-25 | Bernett Matthew J | Optimized ca9 antibodies and methods of using the same |
| US7504364B2 (en) | 2002-03-01 | 2009-03-17 | Receptors Llc | Methods of making arrays and artificial receptors |
| US7469076B2 (en) | 2003-09-03 | 2008-12-23 | Receptors Llc | Sensors employing combinatorial artificial receptors |
| EP1613737A4 (en) | 2003-03-28 | 2008-12-03 | Receptors Llc | ARTIFICIAL RECEPTORS COMPRISING REVERSIBLE IMMOBILIZED CONSTRUCTION BLOCKS AND METHODS |
| EP1664778A2 (en) * | 2003-09-03 | 2006-06-07 | Receptors LLC | Nanodevices employing combinatorial artificial receptors |
| US7504365B2 (en) | 2004-09-03 | 2009-03-17 | Receptors Llc | Combinatorial artificial receptors including tether building blocks |
| US7985715B2 (en) | 2004-09-11 | 2011-07-26 | Receptors Llc | Combinatorial artificial receptors including peptide building blocks |
| DOP2006000277A (es) * | 2005-12-12 | 2007-08-31 | Bayer Pharmaceuticals Corp | Anticuerpos anti mn y métodos para su utilización |
| US20140273033A1 (en) * | 2007-04-12 | 2014-09-18 | Universiteit Hasselt | Biomarkers for multiple sclerosis |
| JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| HUE029003T2 (en) * | 2008-05-30 | 2017-01-30 | Xbiotech Inc | IL-1 alpha antibodies |
| DK2839860T3 (da) | 2012-10-12 | 2019-06-17 | Medimmune Ltd | Pyrrolobenzodiazepiner og konjugater deraf |
| ES2687439T3 (es) | 2013-03-13 | 2018-10-25 | Medimmune Limited | Pirrolobenzodiazepinas y conjugados de las mismas |
| EP4001920A1 (en) * | 2014-04-03 | 2022-05-25 | AllerGenis, LLC | Peptides and methods for detecting food allergy |
| EP3193940A1 (en) | 2014-09-10 | 2017-07-26 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| CN109862919A (zh) | 2016-10-11 | 2019-06-07 | 免疫医疗有限公司 | 抗体-药物缀合物联合免疫介导的治疗剂 |
| CA3098103A1 (en) | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Molecular adjuvant |
| US20230372528A1 (en) | 2020-10-16 | 2023-11-23 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| CN117980327A (zh) | 2021-11-03 | 2024-05-03 | 杭州多禧生物科技有限公司 | 抗体的特异性偶联 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP1690935A3 (en) * | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6297051B1 (en) * | 1997-01-24 | 2001-10-02 | Institute Of Virology, Slovak Academy Of Sciences | MN gene and protein |
| WO1995034650A2 (en) * | 1994-06-15 | 1995-12-21 | Ciba Corning Diagnostics Corp. | Mn gene and protein |
| AU758957C (en) * | 1998-10-23 | 2004-08-12 | Institute Of Virology Of The Slovak Academy Of Sciences | MN gene and protein |
| US6689744B2 (en) * | 2000-09-22 | 2004-02-10 | Genentech, Inc. | Notch receptor agonists and uses |
-
2002
- 2002-10-16 AR ARP020103877A patent/AR036833A1/es unknown
- 2002-10-17 DO DO2002000494A patent/DOP2002000494A/es unknown
- 2002-10-17 UY UY27499A patent/UY27499A1/es not_active Application Discontinuation
- 2002-10-18 HU HU0600335A patent/HUP0600335A2/hu unknown
- 2002-10-18 BR BR0213968-5A patent/BR0213968A/pt not_active IP Right Cessation
- 2002-10-18 RU RU2004115112/13A patent/RU2317998C2/ru not_active IP Right Cessation
- 2002-10-18 PE PE2002001031A patent/PE20030473A1/es not_active Application Discontinuation
- 2002-10-18 IL IL16141102A patent/IL161411A0/xx unknown
- 2002-10-18 PL PL02374304A patent/PL374304A1/xx not_active Application Discontinuation
- 2002-10-18 CA CA002463943A patent/CA2463943A1/en not_active Abandoned
- 2002-10-18 CN CNA028254880A patent/CN1606569A/zh active Pending
- 2002-10-18 JP JP2003536404A patent/JP2005528884A/ja active Pending
- 2002-10-18 WO PCT/US2002/033470 patent/WO2003033674A2/en not_active Ceased
- 2002-10-18 US US10/273,541 patent/US7462696B2/en not_active Expired - Fee Related
- 2002-10-18 EP EP02786449A patent/EP1438339A4/en not_active Withdrawn
- 2002-10-18 MX MXPA04003508A patent/MXPA04003508A/es not_active Application Discontinuation
- 2002-10-18 KR KR1020047005716A patent/KR20050037478A/ko not_active Withdrawn
- 2002-10-18 CO CO02094163A patent/CO5370684A1/es unknown
-
2008
- 2008-12-08 US US12/330,504 patent/US20100240100A1/en not_active Abandoned
-
2010
- 2010-02-01 JP JP2010020670A patent/JP2010260845A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PE20030473A1 (es) | 2003-06-26 |
| CO5370684A1 (es) | 2004-02-27 |
| MXPA04003508A (es) | 2004-07-22 |
| UY27499A1 (es) | 2003-05-30 |
| RU2317998C2 (ru) | 2008-02-27 |
| WO2003033674A3 (en) | 2003-08-21 |
| CA2463943A1 (en) | 2003-04-24 |
| US20100240100A1 (en) | 2010-09-23 |
| DOP2002000494A (es) | 2004-05-31 |
| PL374304A1 (en) | 2005-10-03 |
| IL161411A0 (en) | 2004-09-27 |
| JP2010260845A (ja) | 2010-11-18 |
| KR20050037478A (ko) | 2005-04-22 |
| US7462696B2 (en) | 2008-12-09 |
| WO2003033674A2 (en) | 2003-04-24 |
| CN1606569A (zh) | 2005-04-13 |
| BR0213968A (pt) | 2005-05-10 |
| EP1438339A2 (en) | 2004-07-21 |
| HUP0600335A2 (en) | 2006-08-28 |
| US20030077277A1 (en) | 2003-04-24 |
| JP2005528884A (ja) | 2005-09-29 |
| EP1438339A4 (en) | 2008-08-27 |
| RU2004115112A (ru) | 2005-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5370684A1 (es) | Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular | |
| BR112021024544A2 (pt) | Anticorpo monoclonal anti-ceacam5 e método de preparação do mesmo e uso do mesmo | |
| PE20050712A1 (es) | Anticuerpos rg1 | |
| CY1118880T1 (el) | Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
| CY1118549T1 (el) | Χρηση anti-vegf αντισωματος σε συνδυασμο με χημειοθεραπεια για τη θεραπευτικη αγωγη του καρκινου του μαστου | |
| EA200800953A1 (ru) | Человеческие моноклональные антитела к cd70 | |
| PE20071055A1 (es) | Anticuerpos anti mn | |
| MX2009009450A (es) | Anticuerpos monoclonales para he4 y metodos para su uso. | |
| CO6251370A2 (es) | Una molecula de union cd20 humanizda que comprende un dominio variable de cadena pesada de inmunoglobulina (vh) y un dominio variable de cadena liviana de inmunoglobulina (vl) y metodos de uso de la misma | |
| CY1109889T1 (el) | Μορια αντισωματος που εμφανιζουν ειδικοτητα για ανθρωπινο παραγοντα νεκρωσης ογκων α, και χρηση αυτων | |
| AR044927A1 (es) | Metodos y composiciones para tratar la artritis reumatoidea | |
| AR050642A1 (es) | Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/ calicheamicina | |
| CO6351751A2 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos | |
| AR063086A1 (es) | Anticuerpos humanos que se unen a cxcr4 y usos de los mismos | |
| AR059809A1 (es) | Anticuerpos anti-5t4 y sus usos | |
| WO2007109376A3 (en) | Anti-tumor cell antigen antibody therapeutics | |
| ATE488530T1 (de) | Internalisierende antikörper spezifisch für das raag10 zelloberflächenziel | |
| ATE526037T1 (de) | Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen | |
| BR0116763A (pt) | Anticorpos humanos especìficos para terapia seletiva do c ncer | |
| AR047729A1 (es) | Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe) | |
| BRPI0407680A (pt) | métodos para diagnóstico de cáncer e diminuição de metástase por células cancerosas | |
| ES2570627T3 (es) | Ensayo in vitro de Ezrina para el diagnóstico del cáncer colorrectal | |
| CR10996A (es) | Metodo de tratamiento del cancer mediante administracion de combinaciones de il-18 humana | |
| ES2173910T3 (es) | Anticuerpos humanizados dirigidos contra el antigeno a33. | |
| ECSP22041860A (es) | Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |